Table 4.
Incidence of the predefined cardiovascular outcomes during the follow‐up in those patients who received antihypertensive drug therapies (panel a) and in those who remained untreated (panel b) during the follow‐up, according to 4 BP categories
| Parameters | NT | White‐coat HT | Masked HT | Sustained HT | P value |
|---|---|---|---|---|---|
| (a) | |||||
| Composite outcome (MI + Stroke + Any Hospitalization) | 32 (8.5) | 24 (26.9) | 23 (41.8) | 72 (14.8) | <.001 |
| Myocardial infarction | 13 (14.3) | 7 (8.6) | 11 (2.0) | 28 (5.8) | <.001 |
| Stroke | 7 (7.7) | 0 (0.0) | 3 (5.5) | 6 (1.2) | <.001 |
| Hospitalization for any cause | 22 (24.2) | 20 (24.7) | 18 (32.7) | 43 (8.8) | <.001 |
| Hospitalization for HT | 22 (24.2) | 17 (21.0) | 17 (30.9) | 39 (8.0) | <.001 |
| Hospitalization for HF | 1 (1.1) | 4 (4.9) | 5 (9.1) | 6 (1.2) | .001 |
| (b) | |||||
| Composite outcome (MI + Stroke + Any Hospitalization) | 0 (0.0) | 24 (8.9) | 1 (1.1) | 29 (3.4) | <.001 |
| Myocardial infarction | 0 (0.0) | 2 (0.7) | 0 (0.0) | 13 (1.5) | .091 |
| Stroke | 0 (0.0) | 7 (2.6) | 1 (1.1) | 6 (0.7) | .011 |
| Hospitalization for any cause | 0 (0.0) | 15 (5.6) | 0 (0.0) | 11 (1.3) | <.001 |
| Hospitalization for HT | 0 (0.0) | 14 (5.2) | 0 (0.0) | 11 (1.3) | <.001 |
| Hospitalization for HF | 0 (0.0) | 3 (1.1) | 0 (0.0) | 0 (0.0) | .003 |
HF, heart failure; HT, hypertension; MI, myocardial infarction.